Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company recently initiated two Phase I/II clinical trials using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) to treat macular degeneration at UCLA’s Jules Stein Eye Institute and also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. ACT is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, and its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.
ACT’s principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D